The Study of Surgery,Chemotherapy and Autologous T Cells-Based Immunotherapy for Advanced Gastric Cancer.

A Single-centered Clinical Trial of Surgery，Chemotherapy in Combination With Autologous T Cells-Based Immunotherapy for Advanced Gastric Cancer.

Status

UNKNOWN

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02704299

Enrollment

Registered

2016-03-10

Start date

2016-03-31

Completion date

2018-09-30

Last updated

2016-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer.

Brief summary

Evaluate the feasibility ,safety and efficacy of Surgery，Chemotherapy in Combination with Autologous T cells-Based Immunotherapy for Advanced Gastric Cancer.

Detailed description

Safety:AE/SAE Efficacy:immunologic function;FPS

Interventions

BIOLOGICALAutologous T cells-Based Immunotherapy

TCM cells are the subpopulation of T lymphocytes with key characteristics including high potency and long-term memory of specific immunity.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Aged between 18 to 80 years, males and females. * Subjects who understand and sign the consent form for this study. * The pathologically confirmed advanced gastric cancer T3、T4 or T2 and Metastasis in lymph nodes. * Subjects are surgical candidates. * No distant metastasis (M0) and No distant lymph node metastasis. * Expected survival time of at least 6 months.

Exclusion criteria

* Subjects who do not sign the consent form for this study. * The subject has an allergic history of medicine or food. * The subject has uncontrolled or hard-to-control diseases of cardiovascular,liver,kidney or lung,endocrine system. * The subject tests positive for: HIV, hepatitis virus, syphilis or other infectious diseases. * The subject has an history of other malignant tumour. * The subject has history of alcoholism, drug abuse, or mental illness in the 12 years prior to this trial. * The subject has participated in any other clinical trial in the 3 months prior to this trial. * The subject is pregnant, lactating or planning to conceive within the next 24 months. * The subject has any other unsuitable or adverse condition to be determined by the investigator.

Design outcomes

Primary

Measure	Time frame	Description
Progression-Free-Survival(PFS)	24months	The primary objective is to assess progression free survival (PFS).

Secondary

Measure	Time frame
Incidences of adverse events or serious adverse events	24months

Contacts

Primary ContactJiafu / Ji, Doctor

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026